Patents by Inventor Shian-Yi Chiou

Shian-Yi Chiou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterocycle compounds as Tyro3, Axl and MerTK (TAM) family of receptor tyrosine kinase inhibitors
    Patent number: 11407757
    Abstract: Disclosed are compounds of formula (I) below and tautomers, stereoisomers, isotopologues, or pharmaceutically acceptable salts thereof: in which each of variables R1, ring A, L, W, V, and G is defined herein. Also disclosed are a method for treating disease or disorder mediated by Tyro3, Axl, and/or Mer kinase with a compound of formula (I) or a tautomer, stereoisomer, isotopologue, or salt thereof and a pharmaceutical composition containing same.
    Type: Grant
    Filed: December 26, 2018
    Date of Patent: August 9, 2022
    Assignee: Development Center for Biotechnology
    Inventors: Shih-Chieh Yen, Chu-Bin Liao, Hui-Chen Wang, Po-Ting Chen, Yu-Chih Pan, Tsung-Hui Li, Bo-Rong Chen, Shian-Yi Chiou
  • HETEROCYCLE COMPOUNDS AS TYRO3, AXL AND MERTK (TAM) FAMILY OF RECEPTOR TYROSINE KINASE INHIBITORS
    Publication number: 20210009597
    Abstract: Disclosed are compounds of formula (I) below and tautomers, stereoisomers, isotopologues, or pharmaceutically acceptable salts thereof: in which each of variables R1, ring A, L, W, V, and G is defined herein. Also disclosed are a method for treating disease or disorder mediated by Tyro3, Axl, and/or Mer kinase with a compound of formula (I) or a tautomer, stereoisomer, isotopologue, or salt thereof and a pharmaceutical composition containing same.
    Type: Application
    Filed: December 26, 2018
    Publication date: January 14, 2021
    Applicant: Development Center for Biotechnology
    Inventors: Shih-Chieh YEN, Chu-Bin LIAO, Hui-Chen WANG, Po-Ting CHEN, Yu-Chih PAN, Tsung-Hui LI, Bo-Rong CHEN, Shian-Yi CHIOU
  • Quinoxaline compounds as type III receptor tyrosine kinase inhibitors
    Patent number: 10689362
    Abstract: A compound, capable of inhibiting kinases, for the treatments of diseases or disorders mediated by such kinases, has a structure of formula (I): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt thereof. The compound can be used in the treatments of diseases or conditions mediated by CSF-1R, c-KIT, FLT3, or PDGFR kinases. Such diseases or conditions may include cancers, autoimmune diseases, and bone resorptive diseases.
    Type: Grant
    Filed: October 9, 2017
    Date of Patent: June 23, 2020
    Assignee: Development Center for Biotechnology
    Inventors: Shao-Zheng Peng, Chu-Bin Liao, Hung-Kai Chen, Chen-Hsuan Ho, Hung-Jyun Huang, Shian-Yi Chiou
  • QUINOXALINE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS
    Publication number: 20190308949
    Abstract: A compound, capable of inhibiting kinases, for the treatments of diseases or disorders mediated by such kinases, has a structure of formula (I): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt thereof. The compound can be used in the treatments of diseases or conditions mediated by CSF-1R, c-KIT, FLT3, or PDGFR kinases. Such diseases or conditions may include cancers, autoimmune diseases, and bone resorptive diseases.
    Type: Application
    Filed: October 9, 2017
    Publication date: October 10, 2019
    Applicant: Development Center for Biotechnology
    Inventors: Shao-Zheng Peng, Chu-Bin Liao, Hung-Kai Chen, Chen-Hsuan Ho, Hung-Jyun Huang, Shian-Yi Chiou